RPG Active Pharma approves amalgamation of Actis Generics
- RPG Active Pharma approved amalgamation of wholly owned subsidiary Actis Generics on September 25, 2026
- Merger aims to simplify structure, reduce costs, and improve operational efficiencies
- No shares issued as consideration; Actis shares held by RPG Active Pharma will be cancelled
- Combined net worth stands at ₹69.35 crore; Actis contributed ₹45.96 crore in FY26 revenue
*this image is generated using AI for illustrative purposes only.
RPG Life Sciences Limited subsidiary RPG Active Pharma Limited has approved a scheme of amalgamation of its wholly owned subsidiary, Actis Generics Private Limited, with itself.
The Board of Directors of RPG Active Pharma approved the proposal on September 25, 2026. The transaction is subject to approvals from the National Company Law Tribunal and shareholders. Since Actis is already a wholly owned subsidiary, no shares will be issued as consideration for the merger.
Strategic rationale and financial impact
The amalgamation aims to consolidate assets and liabilities into a single entity to streamline the corporate structure. Key benefits cited include cost savings through legal entity rationalization, elimination of duplicate expenses, and improved management oversight. The consolidation is expected to strengthen the balance sheet and net worth of RPG Active Pharma, potentially facilitating better terms with lenders.
The entities operate in complementary areas within the pharmaceutical value chain. Actis Generics engages in manufacturing pharmaceutical, medical chemicals, and botanical products. RPG Active Pharma focuses on manufacturing and marketing active pharmaceutical ingredients.
Financial details of merging entities
As of March 31, 2026, RPG Active Pharma reported a net worth of ₹34.75 crore. The company was incorporated on December 24, 2025, and did not record any revenue from operations in FY26. Actis Generics reported a net worth of ₹34.60 crore and revenue from operations of ₹45.96 crore during FY26.
| Entity | Role | Net Worth (Mar 31, 2026) | Revenue (FY26) | Status |
|---|---|---|---|---|
| RPG Active Pharma Ltd | Transferee | ₹34.75 crore | Nil | Surviving Entity |
| Actis Generics Pvt Ltd | Transferor | ₹34.60 crore | ₹45.96 crore | Amalgamating |
Regulatory and shareholding implications
The transaction falls under Sections 230 to 232 of the Companies Act, 2013. Although the companies are related parties, the transaction does not attract Section 188 requirements per MCA General Circular No. 30/2014. Upon effectiveness, shares of Actis Generics held by RPG Active Pharma will stand cancelled. There will be no change in the shareholding pattern of RPG Life Sciences Limited.
Historical Stock Returns for RPG Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.44% | -4.13% | -2.04% | +35.60% | +20.52% | +319.03% |
What is the expected timeline for obtaining NCLT and shareholder approvals to finalize the amalgamation?
How will the consolidation of Actis Generics' ₹45.96 crore revenue impact RPG Active Pharma's immediate financial reporting and credit ratings?
Will the streamlined corporate structure enable RPG Active Pharma to pursue new API manufacturing capacity expansions or strategic partnerships?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
